Thai H. Ho, MD, PhD
The frontline treatment paradigm of renal cell carcinoma (RCC) has been shaken up over the past year with the success of immunotherapy combinations and the FDA approval of cabozantinib (Cabometyx).
Results from the CheckMate-214 trial indicated that frontline treatment with the combination of nivolumab (Opdivo) and ipilimumab (Yervoy) reduced the risk of death by 32% compared with sunitinib (Sutent) for patients with metastatic RCC.1
Among patients with intermediate- and poor-risk disease the risk reduction was 37%.
... to read the full story